Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) has divulged protein cereblon (CRBN) ligands and its PROTACs reported to be useful for the treatment of cancer.
Researchers at Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and University of Michigan have synthesized proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL) binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety through a linker.
Researchers at Oncopia Therapeutics Inc. (Proteovant Therapeutics Inc.) and University of Michigan have divulged conjugates comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to an estrogen receptor (ER) or zinc finger protein Helios (IKZF2) and/or zinc finger protein Aiolos (IKZF3) moiety through a linker.
Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and the University of Michigan have prepared and tested new protein cereblon (CRBN) ligands expected to be useful for the treatment of cancer and inflammatory disorders.
Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and the University of Michigan have jointly patented molecular glue degraders targeting cereblon (CRBN) and acting as zinc finger protein Helios (IKZF2) degradation inducers.
